Detalhe da pesquisa
1.
Integrative analysis discovers Imidurea as dual multitargeted inhibitor of CD69, CD40, SHP2, lysozyme, GATA3, cCBL, and S-cysteinase from SARS-CoV-2 and M. tuberculosis.
Int J Biol Macromol;
270(Pt 2): 132332, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38768914
2.
The Effective Inhibitory Concentration of Interferon-ß Correlates with Infectivity and Replication Fitness of SARS-CoV-2 Variants.
J Interferon Cytokine Res;
2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38557204
3.
Omicron sub-lineage BA.5 infection results in attenuated pathology in hACE2 transgenic mice.
Commun Biol;
6(1): 935, 2023 09 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37704701
4.
Immunogenicity and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial.
Hum Vaccin Immunother;
19(1): 2203632, 2023 12 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37113012
5.
Ancestral SARS-CoV-2-Driven Antibody Repertoire Diversity in an Unvaccinated Individual Correlates with Expanded Neutralization Breadth.
Microbiol Spectr;
: e0433222, 2023 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36946746
6.
BA.1, BA.2 and BA.2.75 variants show comparable replication kinetics, reduced impact on epithelial barrier and elicit cross-neutralizing antibodies.
PLoS Pathog;
19(2): e1011196, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36827451
7.
A broadly neutralizing monoclonal antibody overcomes the mutational landscape of emerging SARS-CoV-2 variants of concern.
PLoS Pathog;
18(12): e1010994, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36508467
8.
Safety, tolerability and immunogenicity of Biological E's CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study.
Vaccine;
40(49): 7130-7140, 2022 11 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36328879
9.
Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials.
EBioMedicine;
83: 104217, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35970020
10.
Pre-existing antibody levels negatively correlate with antibody titers after a single dose of BBV152 vaccination.
Nat Commun;
13(1): 3451, 2022 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35705548
11.
A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 Delta variant.
PLoS Pathog;
18(4): e1010465, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35482816
12.
Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months.
EBioMedicine;
78: 103938, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35305396